RxDoctor Payments DataLook up a doctor →

Asif Masood, MD

Hematology & Oncology · Pine Bluff, ARNPI 1760448013

Payments from drug & device makers

$14,001in general payments, 2019–2025

Across 770 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$1K
  • Pfizer$762
  • Sanofi$554
  • Lilly USA, LLC$540
  • Eisai Inc.$514
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis89$1,935
AstraZeneca(2 entities)62$1,077
Pfizer53$762
Sanofi25$554
Lilly USA, LLC29$540
Eisai Inc.29$514
Johnson & Johnson25$477
Bayer26$438
Incyte Corporation19$435
AbbVie17$397
Seagen Inc.18$352
Amgen17$343
Boehringer Ingelheim14$336
GSK19$327
Exelixis Inc.22$322
Merck20$273
Bristol Myers Squibb17$273
Gilead(2 entities)16$253
Ipsen Biopharmaceuticals, Inc14$229
EMD Serono, Inc.12$219
E.r. Squibb & Sons, L.L.C.17$214
Takeda Pharmaceuticals U.S.A., Inc.11$210
Rigel Pharmaceuticals, Inc.14$209
Tesaro, Inc.6$202
Daiichi Sankyo Inc.12$199
Genentech USA, Inc.11$199
ADC Therapeutics America, Inc.10$183
Regeneron Healthcare Solutions, Inc.8$175
Mirati Therapeutics, Inc.5$160
Puma Biotechnology, Inc.10$160
Pharmacyclics LLC, An Abbvie Company10$159
Array Biopharma Inc9$148
Caris MPI, Inc.4$140
Beigene USA, Inc.7$130
Dova Pharmaceuticals8$108
Adaptive Biotechnologies Corporation5$104
Sobi, Inc5$103
AVEO Pharmaceuticals, Inc.6$102
Karyopharm Therapeutics Inc.5$96
Blueprint Medicines Corporation1$93
Pharmaessentia USA Corporation5$89
Astellas Pharma US Inc5$81
Alnylam Pharmaceuticals Inc.4$69
Clovis Oncology, Inc.16$63
Global Blood Therapeutics, Inc.3$50
Azurity Pharmaceuticals, Inc.3$48
Epizyme, Inc.3$47
G1 Therapeutics, Inc.3$43
Geron Corporation2$41
Recordati_rare_diseases_inc.2$40
Lexicon Pharmaceuticals, Inc.2$31
Apellis Pharmaceuticals, Inc.1$30
Beone Medicines USA, Inc.2$30
Pharmacosmos Therapeutics Inc.2$28
Teva Pharmaceuticals USA, Inc.2$27
Verity Pharmaceuticals Inc.1$22
Dendreon Pharmaceuticals LLC1$18
Tersera Therapeutics LLC1$17
Sun Pharmaceutical Industries Inc.1$16
Deciphera Pharmaceuticals Inc.1$16

How this compares

$14,001 in reported general payments places this provider in the 55th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$101,201
Medicare patients
348
Services billed
1,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Pine Bluff

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →